Epstein Secrets

Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region, and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories.

t and XDx, while maintaining board observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Robertson Stephen

quently split to become 2 separate companies), Durata Therapeutics (NLV-II: IPO - July, 2012, NASDAQ: DRTX), and Ilypsa (Sprout IX, exited in sale to Amgen, 6.9x multiple). e Established Private Companies: The New Leaf Team has played the role of lead investor in a large number of private investments. T

reach programs to convey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased clinical trials by 40% and grew patient

ng and outreach programs to convey Mount Sinai’s research capabilities. These efforts attracted ongoing contracts from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. She facilitated over $18 million in grant funding, increased clinical trials by 40% and gr

ontracts and right of first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. e Grew research revenue by increasing clinical trials by 40% and patient enrollment by over 320% ann

ongoing contracts and right of first refusal in phase III clinical trials (with appropriate patient populations) from Novartis, Smith Kline Beecham, Amgen and Pfizer and other pharmaceutical and biotech companies. e Grew research revenue by increasing clinical trials by 40% and patient enrollment by ov

its. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume the risks of

approval. Regardless of the risks, many drug companies are making huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a

from statins do not have those elevated muscle enzymes, says Nissen, the Cleveland Clinic cardiologist, who is conducting a clinical trial Amgen and Pfizer, which is also developing a similar cholesterol drug. He says he has patients who are "desperate" to take a statin but who cannot tolerate it becau

he gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition

, RTN, SSH, STML Shareholder Meetings: ATK, CA, ENV, MCK, GNMT, EA Equity/Mixed Shelfs: EQR Other Newspaper Articles & Stories Barron's positive: Pfizer (PFE) WSJ WSJ negative: Outlook for potash WSJ WSJ positive: Barclays (BARC LN) WSJ EFTA00386265 • Manning found not guilty of aiding enemy FT

ring @ 9pmn* ""AB,ADT,AMT,CMCSA,EXC,GRMN,H,IVZ, LVL,MA reporting pre-open"" "*ALL,CBS,DOX,DWA,MAR,MCHP,MET,WFM,YELP reporting after the close"' • Amgen revs beat ests & boosts y reps view but profit fell on higher costs (trading -1.8%) • Buffalo Wild Wings Q3 eps beat (sss weakened in July) & net j

the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition

from statins do not have those elevated muscle enzymes, says Nissen, the Cleveland Clinic cardiologist, who is conducting a clinical trial Amgen and Pfizer, which is also developing a similar cholesterol drug. He says he has patients who are “desperate” to take a statin but who cannot tolerate it because

the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition

from statins do not have those elevated muscle enzymes, says Nissen, the Cleveland Clinic cardiologist, who is conducting a clinical trial Amgen and Pfizer, which is also developing a similar cholesterol drug. He says he has patients who are “desperate” to take a statin but who cannot tolerate it because